English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Non-small cell lung cancer (NSCLC) remains a world-wide health issue, accounting for 85% of all lung cancers, of which there were an estimated 2.1 million new cases and 1.76 million deaths in 2018; equivalent to 11.6% of the global cancer burden. This incidence is expected to rise in the coming years as rates of smoking increase in developing countries. NSCLC remains more difficult to treat than many other cancer types, with a poor prognosis and limited response to many of the treatments developed in recent decades. Many patients present at an advanced disease state, decreasing the chance of treatment success. Effective treatments for this disease therefore remain a substantially urgent and unmet need.

european oncology and haematology

Targeting Tyrosine-protein Kinase Receptor (<i>MET</i>) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study

Targeting Tyrosine-protein Kinase Receptor (MET) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study